Enliven Therapeutics
As of the edition of 20 October 2026, Enliven Therapeutics runs 3 drugs; it is on route A at 1 target and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Active | 2 |
| Stopped | 1 |
| Total | 3 |
Where it needs a new molecule
Route A at 1 target, route B at 0 targets.
| Target | Route |
|---|---|
| PDE9A High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A | Route A |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where Enliven Therapeutics needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 4 trials led
- Blood and lymph: 3 trials led
- Digestive system: 1 trials led